scPharmaceuticals Inc. (NASDAQ:SCPH) Short Interest Update

scPharmaceuticals Inc. (NASDAQ:SCPH) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 4,250,000 shares, a decline of 15.0% from the August 31st total of 5,000,000 shares. Based on an average daily volume of 264,000 shares, the short-interest ratio is currently 16.1 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a report on Monday, August 19th.

Institutional Investors Weigh In On scPharmaceuticals

Large investors have recently added to or reduced their stakes in the business. AIGH Capital Management LLC increased its position in scPharmaceuticals by 3.4% during the 2nd quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock worth $15,244,000 after buying an additional 115,206 shares during the period. Rubric Capital Management LP raised its stake in scPharmaceuticals by 29.0% in the 4th quarter. Rubric Capital Management LP now owns 3,500,000 shares of the company’s stock worth $21,945,000 after purchasing an additional 786,713 shares in the last quarter. King Luther Capital Management Corp raised its stake in scPharmaceuticals by 51.8% in the 2nd quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock worth $9,592,000 after purchasing an additional 752,005 shares in the last quarter. Rice Hall James & Associates LLC boosted its holdings in scPharmaceuticals by 76.9% in the 2nd quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock valued at $2,163,000 after purchasing an additional 216,122 shares during the period. Finally, Bank of Montreal Can acquired a new position in shares of scPharmaceuticals during the 2nd quarter worth approximately $1,544,000. Institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Stock Up 4.3 %

Shares of SCPH traded up $0.19 during mid-day trading on Friday, hitting $4.61. 211,285 shares of the company’s stock were exchanged, compared to its average volume of 264,751. The company has a debt-to-equity ratio of 4.32, a current ratio of 4.84 and a quick ratio of 3.66. scPharmaceuticals has a 52 week low of $3.24 and a 52 week high of $7.15. The company has a market cap of $230.64 million, a PE ratio of -3.11 and a beta of 0.13. The company has a 50-day simple moving average of $4.95 and a 200 day simple moving average of $4.67.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.44) EPS for the quarter, meeting analysts’ consensus estimates of ($0.44). The firm had revenue of $8.05 million during the quarter, compared to analysts’ expectations of $8.04 million. scPharmaceuticals had a negative net margin of 252.18% and a negative return on equity of 201.84%. On average, research analysts forecast that scPharmaceuticals will post -1.34 earnings per share for the current fiscal year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.